Abstract
ful PCI (clopidogrel = 42; prasugrel = 41). Twelve to 24 hours after receiving the loading dose, patients treated with prasugrel presented greater platelet inhibition compared to those treated with clopidogrel evaluated with the VerifyNow-P2Y12 system [median 49 (9-78) vs. 160 (82-224), respectively, p < 0.001]. Prasugrel has greater clinical efficacy compared to clopidogrel due to its better pharmacodynamic profile. This was demonstrated by the TRITON (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel) TIMI (Thrombolysis in Myocardial Infarction) trial, which reported a significant reduction in death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (12) Yet, this reduction in the incidence of ischemic events was at the expense of a higher rate of bleeding in patients treated with prasugrel, although these patients had greater net clinical benefit. (12)
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
